What is the recommended treatment regimen for uncomplicated genital Chlamydia trachomatis infection in non‑pregnant adults and in pregnant patients?

Treatment of Uncomplicated Genital Chlamydia trachomatis

Non-Pregnant Adults

For uncomplicated genital chlamydia in non-pregnant adults, treat with either azithromycin 1 g orally as a single dose OR doxycycline 100 mg orally twice daily for 7 days 1, 2. Both regimens are equally effective with microbial cure rates of 97-98% 2.

Choosing Between First-Line Options

• Use azithromycin when:

  • Compliance with a 7-day regimen is questionable
  • Patient has erratic health-care seeking behavior
  • Direct observed therapy is needed
  • Immediate treatment completion is essential

• Use doxycycline when:

  • Cost is a concern (significantly less expensive)
  • Patient can reliably complete 7 days of therapy
  • Patient is adherent to medication regimens

The evidence shows these are truly equivalent in efficacy 2, so the choice hinges entirely on compliance likelihood and cost considerations.

Alternative Regimens (if first-line options contraindicated or not tolerated)

• Erythromycin base 500 mg orally four times daily for 7 days
• Erythromycin ethylsuccinate 800 mg orally four times daily for 7 days
• Ofloxacin 300 mg orally twice daily for 7 days
• Levofloxacin 500 mg orally once daily for 7 days 1, 2

Important caveat: Erythromycin has inferior compliance due to frequent gastrointestinal side effects 2. The fluoroquinolones (ofloxacin, levofloxacin) offer no dosing advantage and are more expensive than doxycycline 1.

---

Pregnant Patients

For pregnant women with chlamydia, treat with erythromycin base 500 mg orally four times daily for 7 days OR amoxicillin 500 mg orally three times daily for 7 days 1, 3.

Key Pregnancy Considerations

• Doxycycline and all fluoroquinolones are absolutely contraindicated in pregnancy 1, 3
• Azithromycin 1 g single dose is listed as an alternative, though earlier guidelines noted insufficient data for routine use 3. More recent evidence suggests it may be safe and effective 1
• Erythromycin estolate is contraindicated due to drug-related hepatotoxicity in pregnancy 1, 3

Alternative Regimens for Pregnancy

• Erythromycin base 250 mg orally four times daily for 14 days
• Erythromycin ethylsuccinate 800 mg orally four times daily for 7 days
• Erythromycin ethylsuccinate 400 mg orally four times daily for 14 days
• Azithromycin 1 g orally as single dose 1, 3

Critical Follow-Up in Pregnancy

Pregnant women require repeat testing (preferably by culture) 3 weeks after completing therapy 1, 3. This is essential because:

• None of the pregnancy-safe regimens are as highly efficacious as doxycycline/azithromycin
• Gastrointestinal side effects of erythromycin frequently reduce compliance
• Untreated maternal infection can transmit to the infant during birth, causing neonatal conjunctivitis or pneumonia

---

Universal Management Principles

Sexual Abstinence

Patients must abstain from sexual intercourse for 7 days after single-dose therapy OR until completion of a 7-day regimen 1, 2. Continue abstinence until all sex partners complete treatment to prevent reinfection.

Partner Management

• Evaluate and treat sex partners who had contact within 60 days preceding symptom onset or diagnosis 1
• Treat the most recent partner even if contact was >60 days prior 1
• Partners should receive the same treatment as the index patient

Test of Cure

• Not routinely recommended for non-pregnant patients treated with doxycycline or azithromycin unless symptoms persist or reinfection suspected 1, 2
• Testing <3 weeks after treatment completion can yield false results 1
• Required for pregnant women at 3 weeks post-treatment 1

Rescreening for Reinfection

Retest all women approximately 3 months after treatment 2. This is distinct from test-of-cure. Most post-treatment infections represent reinfection (often because partners weren't treated), and repeat infection significantly elevates PID risk compared to initial infection 1, 2.

HIV-Infected Patients

Use the same treatment regimens as HIV-negative patients 1.

---

Common Pitfalls

1. Confusing test-of-cure with rescreening: Test-of-cure checks treatment success at 3 weeks; rescreening detects reinfection at 3 months
2. Testing too early: NAATs <3 weeks post-treatment may detect dead organisms, yielding false-positives 1
3. Using azithromycin in pregnancy without counseling: While increasingly accepted, inform patients about limited historical data
4. Forgetting partner treatment: This is the primary cause of reinfection and treatment failure
5. Not dispensing medication on-site: Directly observed first dose maximizes compliance 2